Malenka Robert C. 4
4 · MapLight Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
MapLight (MPLT) Director Robert Malenka Sells Shares
What Happened Robert C. Malenka, a director of MapLight Therapeutics (MPLT), sold a total of 7,040 shares in open-market transactions: 7,039 shares on 2026-02-02 at a weighted average price of $18.02 for $126,843, and 1 share on 2026-02-03 at $18.00 for $18. The filing indicates these sales were made to cover tax obligations related to the settlement of restricted stock units (RSUs), a routine tax-withholding sale rather than a directional bet on the company.
Key Details
- Transaction dates and prices: 2026-02-02 — 7,039 shares at a weighted average $18.02 (sales ranged $18.00–$18.14); 2026-02-03 — 1 share at $18.00. Total proceeds ≈ $126,861.
- Shares owned after the transaction: not specified in the Form 4; filing notes the shares are held by the Robert C. Malenka Living Trust (the reporting person is sole trustee with voting/dispositive power).
- Footnotes: F1 — sales to cover tax withholding on RSU settlement; F2 — reported price is a weighted average, multiple sale prices within $18.00–$18.14; F3 — shares held in Malenka living trust.
- Timeliness: Report filed 2026-02-04 for transactions occurring 2026-02-02 and 2026-02-03 (filed within the standard Form 4 reporting window).
Context These sales were tied to RSU tax withholding (common when restricted units vest) and are typically considered routine administrative transactions rather than a strong signal about insider sentiment. The filing also notes retained securities remain subject to a 180‑day IPO lock-up tied to the company’s October 26, 2025 prospectus.
Insider Transaction Report
- Sale
Voting Common Stock
[F1][F2]2026-02-02$18.02/sh−7,039$126,843→ 358,234 total - Sale
Voting Common Stock
[F1]2026-02-03$18.00/sh−1$18→ 358,233 total
- 31,672(indirect: See footnote)
Voting Common Stock
[F3]
Footnotes (3)
- [F1]Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.
- [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.